The National Medical Products Administration (NMPA) stated that during the '15th Five-Year Plan' period, it will strongly support innovation and development in the biomanufacturing industry, promoting the pharmaceutical sector’s transformation from 'follower-style innovation' to 'systematic innovation,' from 'scale-and-speed-driven growth' to 'quality-and-efficiency-oriented growth,' and from 'traditional business models' to 'digitalized supply chains.'
The authorities noted that this year, the country will closely monitor frontier technology areas such as new target and mechanism-based drugs, AI-driven drug discovery, as well as cell and gene therapies. Through four expedited approval pathways, drug approvals will be accelerated. Additionally, efforts will be made to effectively implement a data protection system for clinical trial data and establish market exclusivity periods for pediatric medicines and treatments for rare diseases.
